FDA Warns Online GLP-1 Seller RonanRx Over 'FDA-Approved' and 'American Made' Claims

FDA's Office of Compounding Quality and Compliance has warned RonanRx, Inc., an Elgin, Texas firm selling compounded semaglutide and tirzepatide online, that marketing on its website and social media misbrands those products under federal law. The October 30 warning letter, MARCS-CMS 737905, identifies three categories of false or misleading claims, gives the firm fifteen working days to respond, and warns that failing to address the violations may bring legal action without further notice, including seizure and injunction. [1]

What the letter cites

First, identity. Product images on ronanrx.com and on the @Ronan_Rx account on X show "RonanRx" on the pictured labels, suggesting RonanRx is the compounder of those tirzepatide products "when in fact it is not." [1]

Second, approval and evidence claims. The website described products as "Well-Studied Compounded Medications" and "FDA-Approved Compounded Medications," the latter explained as "Compounded medications whose active ingredient has at least one FDA-approved branded form for the indication described." The X bio read "Explore GLP-1s like Ozempic," and a video pinned at the top of the feed told viewers, "Yea, seventy-eight dollars a month, for drugs like Ozempic. But are our drugs even legit? No. Our drugs are super [bleep] legit." [1]

Third, origin. The same video described the products as "American made" and "farm-to-table drugs" and closed with confetti around an unfurled American flag. FDA's records contain no drug listings for semaglutide or tirzepatide active ingredients intended for compounding that identify a U.S. establishment registered with FDA as the drug substance manufacturer, so the letter says the claims "conceal the true origin of your products." [1]

Why the disclaimers did not help

The letter's central line is direct: "Compounded drug products are not FDA-approved." RonanRx's own disclaimers, including one noting that a specific compounded preparation "may not itself be FDA-approved," did not cure the problem, because they "do not cure the misleading overall impression created by these claims." [1]

The legal framing is misbranding. A drug is misbranded if its labeling is "false or misleading in any particular" under section 502(a) of the FD&C Act, and a compounded drug is misbranded if its advertising or promotion is false or misleading under section 502(bb). Introducing misbranded products into interstate commerce is a prohibited act under section 301(a), and the letter notes that compounded drugs must meet the conditions of sections 503A or 503B to be exempt from new drug approval requirements. [1]

The evidence was the marketing itself

The violations "were identified and documented during a review" of the website and social media platforms in September 2026. No facility inspection was needed: the promotional content is the exhibit. A closing footnote advises the firm to "reassess your advertisements and promotional materials across all platforms, including television and social media." [1]

That method matters well beyond one Texas seller. Clinics, pharmacies and telehealth brands marketing compounded GLP-1s should read the letter as a map of what FDA screenshots: approval-adjacent phrases, domestic-origin claims and casual "legit" talk all count as labeling.

Also on FDA's books: a sterility recall

A separate FDA enforcement record shows Apothecary Pharma LLC of Cary, North Carolina voluntarily recalling compounded injectables for "Lack of Assurance of Sterility." The ongoing Class II action covers 22 vials of Tirzepatide Injection (18 mg/mL, 4 mL multi-dose), across 22 lots listed as AP-202622 through AP-202644 with beyond-use dates from October 7 through November 26, plus one vial of NAD+ Injection (200 mg/mL, 6 mL), lot AP-202647. The firm initiated the recall September 24 and notified customers by letter; FDA classified it Class II on October 8, meaning use may cause temporary or medically reversible health problems and serious harm is unlikely. Sterility not being assured is not the same as contamination being found. [2][3]

Clinics that buy compounded tirzepatide or NAD+ from outside suppliers should check inventory against those lots and confirm they received the recall notice. Neither action affects FDA-approved brands such as Zepbound, Mounjaro, Ozempic or Wegovy. [2][3]

"Compounded drug products are not FDA-approved."

What it means for a clinic: The letter and the recall frame the current line on compounded GLP-1s. Marketing language is a documented enforcement target: no compounded drug is FDA-approved, an approved branded active ingredient does not change that, and origin claims can be checked against FDA's own records. Supply diligence stays concrete: compare any compounded tirzepatide or NAD+ stock against the Apothecary lots above, and ask suppliers how they describe their products online, because the letter also notes that receiving misbranded products in interstate commerce is a violation.